Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Evaluación de la inmunidad híbrida y comorbilidades en el sector educativo de México: perspectivas de la vacunación con Cansino/Moderna contra el SARS-CoV-2
Assessing hybrid immunity and comorbidities in the education sector of Mexico: Insights from Cansino/Moderna Vaccination against SARS-CoV-2
DOI:
https://doi.org/10.15446/rsap.v27n3.117724Palabras clave:
Vacunas contra la COVID-19, inmunidad humoral, comorbilidad, anticuerpos (es)COVID-19 vaccines, humoral immunity, comorbidities, antibodies (en)
Descargas
Objetivo Evaluar la inmunidad híbrida y el efecto de las comorbilidades en personas con el esquema de vacunación Cansino/Moderna contra el virus SARS-CoV-2.
Material y Métodos La investigación es de tipo observacional transversal comparativo. Se evaluó a 47 personas pertenecientes al sector educativo del estado de Veracruz, México, con o sin antecedentes de COVID-19 que recibieron el esquema de vacunación Cansino/Moderna. Todos los participantes firmaron un consentimiento informado. La concentración de anticuerpos de clase IgG contra la proteína S del virus SARS-CoV-2 se determinó por medio de la técnica de Elisa indirecto. El análisis estadístico se realizó por medio una prueba T-Student.
Resultados Los individuos con infección previa por SARS-CoV-2 y con esquema de vacunación Cansino/Moderna producen niveles más altos de anticuerpos antiproteína S de clase IgG, en comparación con el grupo sin antecedentes de COVID-19. Por su parte, los individuos con comorbilidades presentaron una baja producción de anticuerpos, incluso aquellos con inmunidad híbrida.
Conclusión Los datos obtenidos indican que la respuesta inmune humoral contra el SAR-S-CoV-2 se produce después de la vacunación con el esquema Cansino/Moderna de manera eficiente y se demuestra la importancia de la inmunidad híbrida en el contexto de la COVID-19, lo que pone de manifiesto el efecto perjudicial de las comorbilidades en la respuesta inmunológica humoral.
Objetive To evaluate hybrid immunity and the effect of comorbidities in people with the Cansino/Moderna vaccination against the SARS-CoV-2.
Methodology A comparative cross-sectional observational study was conducted in the education sector of the State of Veracruz, involving 47 subjects who had previously been infected with SARS-CoV-2 or not, and who had received Cansino/Moderna vaccination. The concentration of anti-Spike IgG antibodies was evaluated using Elisa assay. All participants signed an informed consent. Statistical analysis T-Student was performed.
Results The individuals with previous SARS-CoV-2 infection who received the Cansino/Moderna vaccination had higher levels of anti-Spike IgG antibodies compared to those who had not previously had COVID-19. Moreover, individuals with comorbidities had impaired anti-Spike IgG production despite having hybrid immunity.
Conclusion These findings indicate that antibodies against SARS-CoV-2 are produced after Cansino/Moderna vaccination, emphasizing the significance of hybrid immunity in the context of COVID-19. Additionally, these results underscore the detrimental effect of comorbidities on humoral response, potentially contributing to the increased risk of severe COVID-19 in individuals with underlying health conditions.
Referencias
1. Gostin LO, Gronvall GK. The origins of covid-19 - Why it matters (and why it doesn't). N Engl J Med. 2023; 388(25):2305-8. https://doi.org/10.1056/nejmp2305081.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223):497-506. https://doi.org/10.1016/s01406736(20)30183-5.
3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020; 25(3):2000045. https://doi.org/10.2807/1560-7917.es.2020.25.3.2000045.
4. Reina, J. El SARS-CoV-2, una nueva zoonosis pandémica que amenaza al mundo. Vacunas. 2020; 21(1):17-22. https://doi.org/10.1016/j.vacun.2020.03.001.
5. Domínguez L, Amador C. El origen de COVID-19: lo que se sabe, lo que se supone y (muy poquito) sobre las teorías de complot. Educ Quím. 2020; 31(2):3-11. https://doi.org/10.22201/fq.18708404e.2020.2.75461.
6. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020; 99:47-56. https://doi.org/10.1016/j.ijid.2020.07.029.
7. Chakraborty C, Bhattacharya M, Dhama K. SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: The lessons learned might help to fight against the next pandemic. Vaccines (Basel). 2023; 11(3):682. https://doi.org/10.3390/vaccines11030682.
8. Beladiya J, Kumar A, Vasava Y, Parmar K, Patel D, Patel S, et al. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials. Rev Med Virol. 2024; 34(1):e2507. https://doi.org/10.1002/rmv.2507.
9. Pérez Hernández M, Castillo Chávez LM. Trayectoria tecnológica y productiva de la industria de vacunas humanas en México: perspectivas post Covid-19. Rev. salud pública (Bogotá) [Internet]. 2023; 25(5):1-7. https://doi.org/10.15446/rsap.v25n5.110791.
10. Halperin SA, Ye L, MacKinnon D, Smith B, Cahn PE, Ruiz-Palacios GM, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo controlled phase 3 trial. Lancet. 2022; 399(10321):237–48. https://doi.org/10.1016/s0140-6736(21)02753-7.
11. Kennedy RB. Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine. Lancet. 2022; 399(10321):212-3. https://doi.org/10.1016/S0140-6736(21)02834-8.
12. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 396(10249):479–88. https://doi.org/10.1016/s0140-6736(20)31605-6.
13. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. https://doi.org/10.1056/nejmoa2035389.
14. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1nCoV-19/BNT162b2 vaccination. Nat Med. 2021; 27(9):1525–9. https://doi.org/10.1038/s41591-021-01449-9.
15. Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. J Med Virol. 2022; 94(4):1294–9. https://doi.org/10.1002/jmv.27463.
16. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021; 372(6549):1418–23. https://doi.org/10.1126/science.abh1282.
17. Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021; 372(6549):1413–8. https://doi.org/10.1126/science.abg9175.
18. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination. Sci Immunol. 2021; 6(58). https://doi.org/10.1126/sciimmunol.abi6950.
19. Chavarría Castro DY, Reyes Varón E, Salgado Cordero AM, Irisson Mora I, Morales Bartolo LE, Álvarez-Montero F. Asociación entre SARS-COV-2 y enfermedades crónicas en personal de salud. Un programa de medicina preventiva. Rev. salud pública (Bogotá) [Internet]. 2023; 25(2). https://doi.org/10.15446/rsap.V25n2.105359.
20. Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes Metab Syndr. 2021; 15(2):505-8. https://doi.org/10.1016/j.dsx.2021.02.026.
21. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med. 2022; 386(23):2201-12. https://doi.org/10.1056/nejmoa2118946.
22. Nimmerjahn F, Ravetch JV. Fc-gamma receptors as regulators of immune responses. Nat Rev Immunol. 2008; 8(1):34-47. https://doi.org/10.1038/nri2206.
23. Bowman KA, Stein D, Shin S, Ferbas KG, Tobin NH, Mann C, et al. Hybrid immunity shifts the fc-effector quality of SARS-CoV-2 mRNA vaccine-induced immunity. mBio. 2022; 13(5):e0164722. https://doi.org/10.1128/mbio.01647-22.
24. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020; 36(7):e3319. https://doi.org/10.1002/dmrr.3319.
25. Gaborit B, Fernandes S, Loubet P, Ninove L, Dutour A, Cariou B, et al. Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort. Metabolism. 2023; 142:155412. https://doi.org/10.1016/j.metabol.2023.155412.
26. Yang L, Zeng T, Li Y, Guo Q, Jiang D. Poor immune response to inactivated COVID-19 vaccine in patients with hypertension. Front Med (Lausanne). 2024; 11:1329607. https://doi.org/10.3389/fmed.2024.1329607.
27. Özbay Kurt FG, Lepper A, Gerhards C, Roemer M, Lasser S, Arkhypov I, et al. Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. Front Immunol. 2022; 13:1012526. https://doi.org/10.3389/fimmu.2022.1012526.
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Esta revista provee acceso libre inmediato a su contenido bajo el principio de que hacer disponible gratuitamente investigación al publico apoya a un mayor intercambio de conocimiento global.
Todos los contenidos de esta revista, excepto dónde está identificado, están publicados bajo una Licencia Creative Commons Atribución 4.0.
